PT-141 (Bremelanotide): preparation and storage
Intended for research use only. Not a medicinal product.
Contents (11 sections)
A cyclic peptide with its own terminal group
PT-141, or bremelanotide, is a cyclic melanocortin analogue. Its ring is formed by a side-chain lactam bond rather than a disulfide. It is related to Melanotan II but has a different C-terminal group: a free acid rather than an amide. Identity, charge and molecular weight therefore differ; the names are not synonyms. Check cyclization, terminal groups, stereochemistry and salt form against the specification. The correct amino-acid composition does not establish the correct ring topology.
Formulated glycerin and laboratory controls
Vyleesi lists glycerin among its excipients. If the finished solution is used as a laboratory comparator, controls must account for glycerin and the remaining formulation. This differs from dry PT-141 without those additives. Different signals do not establish different peptide purity. Match bremelanotide concentration and final medium before comparing receptor responses. With an unknown formulation, describe the result as the response to that particular mixture until excipient effects have been separated.
What the official description establishes
The Vyleesi description gives the structure Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH), acetate form and distinction between bremelanotide mass and salt mass. These support analytical-standard checks. The label also describes activity across several melanocortin subtypes; it does not establish absolute MC4R-only selectivity. Comparative experiments must name the receptor subtype and endpoint measured. Retained activity at one receptor after storage does not automatically establish an unchanged interaction profile across the whole panel.
A pharmaceutical formulation does not define dry reagent handling
Licensed Vyleesi is a formulated bremelanotide solution in a specified container. Its label helps establish chemical identity but does not specify dissolution or shelf life for a laboratory lyophilizate. Do not transfer its concentration, excipients or permitted temperature excursions to another vial. For dry PT-141, establish whether the stated milligrams refer to the peptide component or the complete salt form. Then calculate concentration and test dissolution in the chosen analytical matrix.
Mass calculations and working dilutions
An arithmetic example, not a solubility prescription: 2 mg in a final volume of 4 mL gives 0.5 mg/mL, or 500 micrograms/mL. Adding 20 microliters of that stock to 980 microliters of compatible matrix gives 10 micrograms/mL. Then 100 microliters of this solution plus 900 microliters of matrix gives 1 microgram/mL. Use the final volume in the calculation. If the certificate separately establishes peptide mass fraction, apply it according to the labeling convention, without correcting the mass twice. Molarity requires the molecular weight of the confirmed form; do not borrow a value from a related analogue.
Specify the receptor panel
Melanocortin-receptor experiments should identify receptor subtype, species and readout. cAMP in MC4R-expressing cells and a signal in an MC1R system are not interchangeable measures of PT-141 activity. Comparison with Melanotan II requires independently established concentrations, matched exposure time and a vehicle control. A changed cell response can reflect the available peptide fraction after contact with plastic or serum. Check final working dilutions rather than only the original stock.
Avoiding analyte substitution in LC-MS
When PT-141 and MT-II are analyzed in the same laboratory, control injection carryover and peak assignment. Related molecules may have similar properties, but the terminal amide and acid remain distinct groups. Renaming a file does not correct a standard with the wrong terminal form. Use an appropriate standard, expected mass and chromatographic profile; separate isomeric impurities where necessary. In albumin- or serum-containing samples, assess PT-141 extraction and matrix effects on ionization. Calibration in clean water does not establish either.
Ring and storage questions
Does cyclization make the molecule storage-proof? It does not eliminate adsorption, aromatic-residue oxidation or contamination effects. Is a reductant needed to “preserve the ring”? A lactam ring is not a disulfide, so that rationale is incorrect. Is an LC-MS peak at the expected mass sufficient? It is useful, but isomeric material may require additional separation, while function needs separate confirmation. After a temperature excursion, compare chemical profile and receptor response with fresh control material rather than judging clarity alone.
A stored-PT-141 validation plan
Store dry laboratory PT-141 sealed and frozen under supplier conditions; a finished medical product has separate instructions. Define the final solution application before storage. For an MC4R-cAMP assay, check intact-PT-141 recovery after dilution and the full response curve in the same cells. Lower maximum cAMP may reflect cells or vehicle, while curve shifts can also reflect available concentration. Comparing fresh and stored material on one plate helps separate these effects from differences between runs; an independent chemical check is needed to draw conclusions about the reagent itself.
End of article
PT-141 (Bremelanotide)
for laboratory research
Packs and current prices on the product page.